MorphoSys Foresees 10 New Program Starts In 2014, Earnings Deficit

12 Mar 2014

• By Sten Stovall

MorphoSys expects both partnered and proprietary activities to generate around 10 new program starts this year as the German biotech strongly boosts its R&D investment, a plan that will generate its first earnings shortfall in a decade.

German biotech MorphoSys AG’s expects around ten new antibody program starts this year, as it boosts investments in go-it-alone projects to between €36 million to €41 million ($50 million to $57 million) from €32 million in 2013.

The plan will be expensive, taking the German biotech into the red for the first time since 2004.